How Will the Anakinra Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Anakinra Market Grow Over the Forecast Period Based on Its Expected CAGR?
The market size for anakinra has witnessed a swift expansion in the past few years. The market is set to expand from $4.89 billion in 2024 to $5.51 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.8%. The notable growth during the historic period can be linked to the escalating incidence of rheumatoid arthritis, the sanctioning of anakinra usage for uncommon autoinflammatory disorders such as NOMID, increased comprehension of biologics in managing lasting inflammatory conditions, and the burgeoning adoption of targeted treatments.
The market size of anakinra is projected to experience brisk growth in the ensuing years, swelling to a considerable $8.81 billion by 2029 with a compound annual growth rate (CAGR) of 12.4%. The projected growth during the forecast period may be due to the extending use of anakinra in numerous conditions, amplified emphasis on personalized medicine, escalating incidence of rare autoinflammatory disorders, improvements in drug delivery mechanisms, and escalating healthcare accessibility in emerging markets that drive the demand for biologics. Noteworthy trends throughout this period incorporate the evolution of biosimilars and next-generation IL-1 inhibitors, the uptake of home and self-treatment options, alliances between biotech corporations and academic entities, and digital health solutions to boost patient adherence.
Which Major Market Drivers Are Expected to Boost the Anakinra Market’s Growth Potential?
A surge in the occurrence of autoimmune diseases is projected to foster the expansion of the anakinra market. Autoimmune diseases occur when the body’s immune system mistakenly attacks and destroys its own healthy tissues and organs, mistaking them as foreign bodies. The surge of these illnesses is fueled by genetic susceptibility and environmental influences, including infections, contaminations, and changes in diet, which together raise the prevalence rate. Anakinra is employed to manage autoimmune diseases by inhibiting interleukin-1 (IL-1) activity and lessening inflammation in conditions like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, a report from the Australian Institute of Health and Welfare, a governmental entity in Australia, disclosed that hospitalizations for rheumatoid arthritis reached 10,000 in the 2021-22 period, marking a 25% escalation from the prior year’s 8,000, which represents a rate of 39 hospitalizations for every 100,000 individuals. Therefore, the surge in autoimmune diseases is stimulating the anakinra market’s expansion. Influence Of Increasing Healthcare Spending On Market Expansion
Explore Comprehensive Insights Into The Global Anakinra Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp
Who Are the Dominant Players Expanding Their Reach in the Anakinra Market?
Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.
What Are the Top Trends Shaping the Evolution of the Anakinra Market?
Key players in the Anakinra market are securing regulatory greenlights to widen the scope for new therapeutic uses. Such approvals signify official sanctions from regulatory bodies that permit a medication to be sold and prescribed for particular health conditions after scrutinizing its safety, efficacy, and quality. For instance, in November 2022, Kineret (anakinra) received an Emergency Use Authorization (EUA) from the Food and Drug Administration, a US regulatory body, for the treatment of adult patients admitted to a hospital due to COVID-19-induced pneumonia who require additional oxygen. The intent was to mitigate the chances of acute respiratory failure. This authorization stemmed from the SAVE-MORE phase 3 trial which unveiled that early administration of Kineret led to improved patient prognosis. Kineret operates by inhibiting cytokines IL-1a and IL-1ß, which escalate the hyperinflammatory response seen in acute COVID-19 instances. Though Kineret is not yet fully sanctioned by the FDA for this use, it is temporarily approved for application amid the ongoing public health crisis.
Secure Your Global Anakinra Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report
Which Market Segments Are Driving Strategic Growth and Trends in the Anakinra Market?
The anakinra market covered in this report is segmented –
1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease
2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease
3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms
4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares
5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction
6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management
7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis
Which Regions Are Setting the Pace for Anakinra Market Growth?
North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Anakinra Market Defined Across Different Regions?
Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications.
Browse Through More Similar Reports By The Business Research Company:
Chemotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Hormone Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Gastrointestinal Bleeding Treatment Devices Size Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
